Caseware UK (AP4) 2024.0.164 2024.0.164 2025-07-31 2025-07-31 true 2024-08-01 false No description of principal activity 2 2 true The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 11488933 2024-08-01 2025-07-31 11488933 2023-08-01 2024-07-31 11488933 2025-07-31 11488933 2024-07-31 11488933 c:Director1 2024-08-01 2025-07-31 11488933 c:Director2 2024-08-01 2025-07-31 11488933 c:RegisteredOffice 2024-08-01 2025-07-31 11488933 d:OfficeEquipment 2025-07-31 11488933 d:OfficeEquipment 2024-07-31 11488933 d:FreeholdInvestmentProperty 2025-07-31 11488933 d:FreeholdInvestmentProperty 2024-07-31 11488933 d:FreeholdInvestmentProperty 2 2024-08-01 2025-07-31 11488933 d:CurrentFinancialInstruments 2025-07-31 11488933 d:CurrentFinancialInstruments 2024-07-31 11488933 d:CurrentFinancialInstruments d:WithinOneYear 2025-07-31 11488933 d:CurrentFinancialInstruments d:WithinOneYear 2024-07-31 11488933 d:ShareCapital 2025-07-31 11488933 d:ShareCapital 2024-07-31 11488933 d:InvestmentPropertiesRevaluationReserve 2024-08-01 2025-07-31 11488933 d:InvestmentPropertiesRevaluationReserve 2025-07-31 11488933 d:InvestmentPropertiesRevaluationReserve 2024-07-31 11488933 d:RetainedEarningsAccumulatedLosses 2024-08-01 2025-07-31 11488933 d:RetainedEarningsAccumulatedLosses 2025-07-31 11488933 d:RetainedEarningsAccumulatedLosses 2024-07-31 11488933 c:OrdinaryShareClass1 2024-08-01 2025-07-31 11488933 c:OrdinaryShareClass1 2025-07-31 11488933 c:OrdinaryShareClass2 2024-08-01 2025-07-31 11488933 c:OrdinaryShareClass2 2025-07-31 11488933 c:FRS102 2024-08-01 2025-07-31 11488933 c:AuditExemptWithAccountantsReport 2024-08-01 2025-07-31 11488933 c:FullAccounts 2024-08-01 2025-07-31 11488933 c:PrivateLimitedCompanyLtd 2024-08-01 2025-07-31 11488933 d:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2024-08-01 2025-07-31 11488933 d:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2025-07-31 11488933 d:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2024-07-31 11488933 2 2024-08-01 2025-07-31 11488933 6 2024-08-01 2025-07-31 11488933 f:PoundSterling 2024-08-01 2025-07-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 11488933 NABMED LIMITED UNAUDITED FINANCIAL STATEMENTS INFORMATION FOR FILING WITH THE REGISTRAR FOR THE YEAR ENDED 31 JULY 2025
NABMED LIMITED COMPANY INFORMATION
Directors | N Hujairi
| R Ghandour-Hujairi
Registered number | 11488933
Registered office | 7 The Close
| Norwich
| Norfolk
| NR1 4DJ
Accountants | MA Partners LLP
| Chartered Accountants
| 7 The Close
| Norwich
| Norfolk
| NR1 4DJ
NABMED LIMITED CONTENTS
| Page
Accountants' report | 1
Balance sheet | 2 - 3
Notes to the financial statements | 4 - 9
NABMED LIMITED CHARTERED ACCOUNTANTS' REPORT TO THE BOARD OF DIRECTORS ON THE PREPARATION OF THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OF NABMED LIMITED FOR THE YEAR ENDED 31 JULY 2025 In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of NabMed Limited for the year ended 31 July 2025 which comprise the Balance sheet and the related notes from the Company's accounting records and from information and explanations you have given us. As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at https://www.icaew.com /regulation. This report is made solely to the Board of directors of NabMed Limited, as a body, in accordance with the terms of our engagement letter dated 24 August 2021. Our work has been undertaken solely to prepare for your approval the financial statements of NabMed Limited and state those matters that we have agreed to state to the Board of directors of NabMed Limited, as a body, in this report in accordance with ICAEW Technical Release TECH07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than NabMed Limited and its Board of directors, as a body, for our work or for this report. It is your duty to ensure that NabMed Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of NabMed Limited. You consider that NabMed Limited is exempt from the statutory audit requirement for the year. We have not been instructed to carry out an audit or review of the financial statements of NabMed Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements. MA Partners LLP Chartered Accountants 7 The Close Norwich Norfolk NR1 4DJ 29 October 2025 Page 1
NABMED LIMITED REGISTERED NUMBER: 11488933 BALANCE SHEET AS AT 31 JULY 2025
|  | 2025 |  | 2024
Note |  | £ |  | £
Fixed assets |  |  |  |  |
Investments | 5 |  | 701,006 |  | 579,138
Investment property | 6 |  | 102,954 |  | 110,000
|  |  | 803,960 |  | 689,138
Current assets |  |  |  |  |
Debtors: amounts falling due within one year | 7 | 38,926 |  | 63,150 |
Cash at bank and in hand |  | 241,805 |  | 225,008 |
|  | 280,731 |  | 288,158 |
Creditors: amounts falling due within one year | 8 | (117,259) |  | (126,087) |
Net current assets |  |  | 163,472 |  | 162,071
Total assets less current liabilities |  |  | 967,432 |  | 851,209
Net assets |  |  | 967,432 |  | 851,209
Capital and reserves |  |  |  |  |
Called up share capital | 9 |  | 100 |  | 100
Investment property revaluation reserve | 10 |  | (11,250) |  | 46,530
Profit and loss account | 10 |  | 978,582 |  | 804,579
|  |  | 967,432 |  | 851,209
Page 2
NABMED LIMITED REGISTERED NUMBER: 11488933 BALANCE SHEET (CONTINUED) AS AT 31 JULY 2025 The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements. The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities. The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime. The financial statements were approved and authorised for issue by the board and were signed on its behalf on 29 October 2025.
N Hujairi
Director
The notes on pages 4 to 9 form part of these financial statements. Page 3
NABMED LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JULY 2025
1. | General information
The Company is a private company limited by shares. It is both incorporated and domiciled in England and Wales. The address of its registered office is 7 The Close, Norwich, Norfolk, NR1 4DJ. The Company's principal activity is that of the provision of radiology services and the Company's principal place of business is Chelsea, London. 2.Accounting policies
| 2.1 | Basis of preparation of financial statements
The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view. The following principal accounting policies have been applied:
| 2.2 | Revenue
Revenue is measured at the fair value of the consideration received or receivable. Revenue for radiology services is recognised in the period in which the services are provided.
| 2.3 | Interest income
Interest income is recognised in profit or loss using the effective interest method.
| 2.4 | Pensions
Defined contribution pension plan The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations. The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance sheet. The assets of the plan are held separately from the Company in independently administered funds.
| 2.5 | Current and deferred taxation
The tax expense for the year comprises current and deferred tax. Deferred tax balances are recognised in respect of timing differences that have originated but not reversed by the balance sheet date. The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income. Page 4
NABMED LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JULY 2025 2.Accounting policies (continued)
| 2.6 | Investment property
Investment property is carried at fair value determined annually by external valuers and derived from the current market rents and investment property yields for comparable real estate, adjusted if necessary for any difference in the nature, location or condition of the specific asset. No depreciation is provided. Changes in fair value are recognised in profit or loss.
| 2.7 | Valuation of investments
Investments in unlisted Company shares, whose market value can be reliably determined, are remeasured to market value at each balance sheet date. Gains and losses on remeasurement are recognised in the Profit and loss account for the period. Where market value cannot be reliably determined, such investments are stated at historic cost less impairment.
| 2.8 | Debtors
Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.
| 2.9 | Cash and cash equivalents
Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.
| 2.10 | Creditors
Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.
| 2.11 | Financial instruments
The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments. Financial instruments are recognised in the Company's Balance sheet when the Company becomes party to the contractual provisions of the instrument. Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously. Basic financial assets Basic financial assets, which include trade and other receivables, cash and bank balances, are initially measured at their transaction price including transaction costs and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Page 5
NABMED LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JULY 2025 2.Accounting policies (continued)
| 2.11 | Financial instruments (continued)
Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other receivables due with the operating cycle fall into this category of financial instruments. Other financial assets Other financial assets, which includes investments in equity instruments which are not classified as subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the recognised transaction price. Such assets are subsequently measured at fair value with the changes in fair value being recognised in the profit or loss. Where other financial assets are not publicly traded, hence their fair value cannot be measured reliably, they are measured at cost less impairment. Impairment of financial assets Financial assets are assessed for indicators of impairment at each reporting date. Financial assets are impaired when events, subsequent to their initial recognition, indicate the estimated future cash flows derived from the financial asset(s) have been adversely impacted. The impairment loss will be the difference between the current carrying amount and the present value of the future cash flows at the asset(s) original effective interest rate. If there is a favourable change in relation to the events surrounding the impairment loss then the impairment can be reviewed for possible reversal. The reversal will not cause the current carrying amount to exceed the original carrying amount had the impairment not been recognised. The impairment reversal is recognised in the profit or loss. Other financial instruments Derivatives, including forward exchange contracts, futures contracts and interest rate swaps, are not classified as basic financial instruments. These are initially recognised at fair value on the date the derivative contract is entered into, with costs being charged to the profit or loss. They are subsequently measured at fair value with changes in the profit or loss. Debt instruments that do not meet the conditions as set out in FRS 102 paragraph 11.9 are subsequently measured at fair value through the profit or loss. This recognition and measurement would also apply to financial instruments where the performance is evaluated on a fair value basis as with a documented risk management or investment strategy. Derecognition of financial assets Financial assets are derecognised when their contractual right to future cash flow expire, or are settled, or when the Company transfers the asset and substantially all the risks and rewards of ownership to another party. If significant risks and rewards of ownership are retained after the transfer to another party, then the Company will continue to recognise the value of the portion of the risks and rewards retained. Page 6
NABMED LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JULY 2025 2.Accounting policies (continued)
| 2.11 | Financial instruments (continued)
Derecognition of financial liabilities Financial liabilities are derecognised when the Company's contractual obligations expire or are discharged or cancelled.
| 2.12 | Dividends
Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.
3. | Employees
| The average monthly number of employees, including directors, during the year was 2 (2024 - 2).
4. | Tangible fixed assets
|  | Office equipment
|  | £
| Cost or valuation |
| At 1 August 2024 | 1,373
| At 31 July 2025 | 1,373
| Depreciation |
| At 1 August 2024 | 1,373
| At 31 July 2025 | 1,373
| Net book value |
| At 31 July 2025 | -
Page 7
NABMED LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JULY 2025
5. | Fixed asset investments
|  | Unlisted investments
|  | £
| Cost or valuation |
| At 1 August 2024 | 579,138
| Additions | 96,028
| Disposals | (3,256)
| Revaluations | 29,096
| At 31 July 2025 | 701,006
6. | Investment property
|  | Freehold investment property
|  | £
| Valuation |
| At 1 August 2024 | 110,000
| Deficit on revaluation | (7,046)
| At 31 July 2025 | 102,954
The 2025 valuations were made by an external consultant.
7. | Debtors
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Trade debtors | 8,017 | 21,881
| Other debtors | 25,000 | 25,000
| Prepayments and accrued income | 2,159 | 1,611
| Deferred taxation | 3,750 | 14,658
|  | 38,926 | 63,150
Page 8
NABMED LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JULY 2025
8. | Creditors: Amounts falling due within one year
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Corporation tax | 109,426 | 120,019
| Other creditors | 5,099 | 3,363
| Accruals and deferred income | 2,734 | 2,705
|  | 117,259 | 126,087
9. | Share capital
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
|  | Allotted, called up and fully paid |  |
|  | 50 A Ordinary shares of £1.00 each | 50 | 50
|  | 50 B Ordinary shares of £1.00 each | 50 | 50
|  |  | 100 | 100
10. | Reserves
Investment property revaluation reserve The fair value reserve represents the cumulative value of revaluations of the Company's investment property to fair value, net of deferred tax. The amounts debited or credited to this reserve are transfers from the profit and loss account. Deferred tax is provided for on these fair value adjustments at the standard rate of corporation tax applicable in the UK. Profit and loss account The profit and loss account includes all current and prior period retained profits and losses.
11. | Related party transactions
| As at 31 July 2025 the balance due to the directors was £3,016 (2024: £1,280).
Page 9